MedTrace Logo

Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration

NCT01835015 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-03-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

CLG561

Administered by intravitreal injection, Day 1

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Head of Clinical Sciences, CA CSI NS/Opth · Alcon Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-11-30
Completion
2014-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01835015 on ClinicalTrials.gov